A Phase 3 interventional study of CKD-843 dose#1 and CKD-843 dose#2 in Androgenetic Alopecia, sponsored by Chong Kun Dang Pharmaceutical. Recruiting at 1 site in South Korea. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
The participants were randomly assigned to one of the following groups: CKD-843 dose #1, CKD-843 dose #2, placebo, or Dutasteride group. They received the assigned medication, placebo for blinding, or the reference drug over a 12-month period.
511 studies on the registry are indexed under Alopecia; 128 are open to participants now.
This study's planned enrollment of 288 is above the median of 50 across 430 interventional studies indexed under Alopecia.
Browse Alopecia studies →Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CKD-843 dose#1 + Placebo of Dutasteride Capsule
Drug: CKD-843 dose#1 · Drug: Placebo of Dutasteride Capsule
CKD-843 dose#2 + Placebo of Dutasteride Capsule
Drug: CKD-843 dose#2 · Drug: Placebo of Dutasteride Capsule
Placebo of CKD-843 dose + Placebo of Dutasteride Capsule
Drug: Placebo of CKD-843 dose · Drug: Placebo of Dutasteride Capsule
Placebo of CKD-843 dose + Dutasteride Capsules
Drug: Placebo of CKD-843 dose · Drug: Dutasteride Capsules
IM injection every 3 months for 12 months
IM injection every 3 months for 12 months
IM injection every 3 months for 12 months
oral, once daily, 12 months
oral, once daily, 12 months
Total number of hair Changes
from Baseline at Week24 of total number of hair changes
Time frame: Baseline, Week 24
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CKD-843
Chong Kun Dang Pharmaceutical →